JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: UBS Global Healthcare Conference (Palm Beach Gardens): Management will participate in one-on-one meetings on November 10, 2025.Stifel 2025 Healthcare Conference (New York): Management will participate in a fireside chat on November 12, 2025 at 8:40 ...

Core Viewpoint - Ligand Pharmaceuticals will report its third quarter 2025 financial results on November 6, 2025, and will hold a conference call to discuss these results and provide a business update [1]. Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3]. - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3]. - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3]. - The company operates two royalty-generating technology platforms: Captisol®, which enhances drug solubility and stability, and NITRICIL™, which allows for tunable dosing and adjustable drug release profiles [3]. - Ligand has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3].

Core Insights - Ligand Pharmaceuticals will participate in upcoming investor conferences, providing opportunities for one-on-one meetings with investors [1][4] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] - The company operates two royalty-generating technology platforms: Captisol® for optimizing drug solubility and stability, and NITRICIL™ for tunable dosing and adjustable drug release profiles [2] Investor Relations - Ligand utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and conference calls [3]

Core Viewpoint - Ligand Pharmaceuticals has successfully completed an offering of 0.75% convertible senior notes due 2030, raising a total of $460 million, with net proceeds of approximately $445.1 million after fees and expenses [1][2]. Group 1: Offering Details - The offering consisted of $460 million in convertible senior notes, including an additional $60 million purchased by initial purchasers [1]. - The net proceeds from the offering were approximately $445.1 million, which will be used for various corporate purposes [2]. Group 2: Use of Proceeds - Ligand allocated approximately $45.9 million of the net proceeds to cover costs associated with convertible note hedge transactions [2]. - The company repurchased 102,034 shares of its common stock for about $15.0 million at a price of $147.01 per share [2]. - Remaining net proceeds are expected to be used for general corporate purposes [2]. Group 3: Financial Instruments - Ligand entered into convertible note hedge transactions to mitigate potential dilution of its common stock upon conversion of the notes [3]. - The company also issued warrants to purchase common stock, with an initial strike price of $294.02 per share, representing a 100% premium over the last reported price [3].

Group 1 - Ligand Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025, and will hold a conference call at 8:30 AM ET to discuss the results and provide a business update [1][2] - The company operates a business model focused on generating value for stockholders through a diversified portfolio of biotech and pharmaceutical product revenue streams, supported by a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization to generate revenue [3] Group 2 - Ligand's Captisol® platform technology optimizes the solubility and stability of drugs, while the NITRICIL™ platform technology allows for tunable dosing and adjustable drug release profiles [3] - The company has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]

Core Insights - Ligand Pharmaceuticals' partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, leading to a $5 million milestone payment for Ligand [1][2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [4] - The company aims to create a diversified portfolio of biotech and pharmaceutical revenue streams while maintaining a low corporate cost structure [4] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [4] Product Details - ZELSUVMI™ (berdazimer) is a nitric oxide-releasing topical gel indicated for treating molluscum contagiosum in patients aged one year and older [3] - It is the first and only approved topical prescription medication that can be applied at home, outside of a medical setting [3] - The product was developed using Ligand's proprietary NITRICIL™ technology platform [3] Financial Aspects - Following the merger between Pelthos Therapeutics and Channel Therapeutics, Ligand now owns 56% of Pelthos [2] - Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and can earn up to an additional $5 million in commercial sales milestones [2]

Core Insights - Pelthos Therapeutics Inc. is set to launch ZELSUVMI™ for treating Molluscum contagiosum infections in July 2025, following the completion of a merger with Channel Therapeutics Corporation [1][2] - Ligand Pharmaceuticals has invested $18 million in Pelthos and will receive a 13% royalty on worldwide sales of ZELSUVMI [1][2] - Pelthos will begin trading on the NYSE American exchange under the ticker symbol "PTHS" on July 2, 2025 [1] Company Developments - The merger between Ligand's subsidiary LNHC, Inc. and Channel Merger Sub Inc. has been completed, forming Pelthos Therapeutics Inc. [1][2] - Pelthos raised $50.1 million in equity capital, with $32 million from a group of strategic investors and $18 million from Ligand [2] - The capital raised will support the commercial launch of ZELSUVMI and includes the cancellation of approximately $18.8 million in bridge capital previously advanced to Pelthos [2] Product Information - ZELSUVMI (berdazimer) is a topical gel approved for treating Molluscum contagiosum, a common skin infection affecting an estimated 16.7 million people in the U.S. [3] - It is the first and only prescription medication for this condition that can be administered at home by patients or caregivers [3] - Pelthos is also evaluating the development of Channel's existing NaV 1.7 programs for various types of chronic pain and post-surgical nerve blocks [3]

Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3] Upcoming Investor Day - Ligand Pharmaceuticals will host an Investor Day in New York City on December 9, 2025, at 10 a.m. Eastern Time [1] - The event will feature presentations from Ligand's senior management team discussing the company's strategy, investment activity, royalty portfolio, and long-term financial outlook [2] - A live webcast of the event will be available on Ligand's Investor Relations website, with a detailed agenda and dial-in information to be provided closer to the event [2] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [3] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [3] - The NITRICIL™ platform allows for tunable dosing and adjustable drug release profiles, targeting a broad range of indications [3] Partnerships and Alliances - Ligand has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]

Core Viewpoint - Ligand Pharmaceuticals is celebrating significant milestones, including the ringing of The Nasdaq Opening Bell, which reflects the company's transformation into a profitable and infrastructure-light organization focused on biopharmaceuticals [2][3]. Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company that supports the clinical development of high-value medicines through financing and licensing technologies [3]. - The company's business model aims to create a diversified portfolio of revenue streams from biotech and pharmaceutical products while maintaining a low corporate cost structure [3]. - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3]. Recent Developments - The company has made significant progress over the past few years, focusing on acquiring and generating royalties from a diverse portfolio of biopharmaceutical products [2]. - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [3]. - Captisol® optimizes drug solubility and stability, while NITRICIL™ allows for tunable dosing and adjustable drug release profiles [3]. Future Commitment - Ligand is committed to building on its recent momentum and supporting partners in developing breakthrough medicines for patients, aiming to create long-term value for shareholders [2].

Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Upcoming Investor Conferences - Ligand management will participate in the H.C. Wainwright Royalty Company Conference on May 13, 2025, at 3:30 p.m. ET, including a fireside chat and one-on-one meetings [4] - Management will also take part in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 2:05 p.m. ET, featuring a fireside chat and one-on-one meetings [4] - Additionally, Ligand will engage in one-on-one meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2025 [4] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [2] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [2] - The NITRICIL™ platform allows for tunable dosing, enabling adjustable drug release profiles for proprietary formulations targeting a broad range of indications [2] Investor Relations - The company utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations under Regulation FD [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and public conference calls [3]